|

Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

RECRUITINGSponsored by Andrés José Maria Ferreri
Actively Recruiting
SponsorAndrés José Maria Ferreri
Started2025-12-01
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07278921

Summary

Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients (\>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.
* Patients who have signed informed consent for treatment.

Exclusion Criteria:

* Age \<18 years
* Patients with other types of cancer/lymphoma
* Patients not eligible for the Mosunetuzumab compassionate use program

Conditions2

CancerRelapsed/Refractory Follicular Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.